KSQ Therapeutics hopes to reduce the time and costs associated with drug development with its proprietary platform for developing targeted therapies, and it has raised $76m and recruited former Sanofi-Genzyme executive David Meeker as its CEO to build a portfolio of drug candidates.
Cambridge, Mass.-based KSQ was founded by academics from four different institutions and two separate venture capital firms to create the...








